Некоторые аспекты лекарственной и нелекарственной терапии болезни Альцгеймера

СтатьяМЕД СОВЕТ. 2015; № 2: 6–9. DOI:10.21518/2079-701X-2015-2-6-9

Котова О.В.^[1]

Акарачкова Е.С.^[1]

^[1]Первый Московский государственный медицинский университет им. И. М. Сеченова (Сеченовский университет)

В статье представлен современный подход к лечению пациентов с болезнью Альцгеймера (БА). Приводятся данные по изучению эффективности антагониста глутаматных NMDA-рецепторов меман-тина при БА, влияния мемантина на когнитивный дефицит, поведенческие симптомы и повседневную активность больных.

нейродегенеративные заболевания

болезнь Альцгеймера

антагонисты глутаматных NMDA-рецепторов

мемантин

Бихевиоральные симптомы

Болезнь

Больные

Возбуждение

Деменция

Европа

Кинез

Мемантин

Плацебо

Риск

Смертность

Человек

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. Alzheimer's disease. Subcell Biochem., 2012, 65: 329-52. doi: 10.1007/978-94-007-5416-4_14..
DOI: 10.1007/978-94-007-5416-4_14

Ashford JW, Schmitt FA, Kumar V. Diagnosis of Alzheimer's disease. Psychiatr Ann, 1998, 26: 262-8.

Livingston G, Katona C, Roch B et al. A dependency model for patients with Alzheimer's disease: its validation and relationship to the costs of care - the LASER-AD Study. Curr Med Res Opin, 2004, S7: 1007-16.

Cummings JL, Cole G. Alzheimer disease. JAMA, 2002, 287: 2335-8.

Reisberg B, Burns A, Brodaty H, et al. Diagnosis of Alzheimer's disease. Report of an International Psychogeriatric Association Special Meeting Work Group under the co-sponsorship of Alzheimer's Disease International, the European Federation of Neurological Societies, the World Health Organization, and the World Psychiatric Association. Int Psychogeriatr, 1997, 9 (Suppl. 1): 11-38.

Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol, 2003, 60: 1119-22.

Fratiglioni L, De Ronchi D, Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging, 1999, 15: 365-75.

Singh B, Parsaik AK, Mielke MM, Erwin PJ, Knopman DS, Petersen RC5, Roberts RO. Association of mediterranean diet with mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis., 2014, 39(2): 271-82. doi: 10.3233/JAD-130830..
DOI: 10.3233/JAD-130830

Abbott A. Dementia: a problem of our age. Nature, 2011, 475(7355): 2-4.

Nicolia V, Lucarelli M, Fuso A. Environment, epi-genetics and neurodegeneration: Focus on nutrition in Alzheimer's disease. Exp Gerontol., 2014, Oct. 14. pii: S0531-5565(14)00281-2. doi: 10.1016/j. exger.2014.10.006..
DOI: 10.1016/j. exger.2014.10.006

Williams PT. Lower Risk of Alzheimer's Disease Mortality with Exercise, Statin, and Fruit Intake. J Alzheimers Dis., 2014, Nov. 14 [Epub ahead of print].

Herrmann N, Chau SA, Kircanski I, Lanctot KL. Current and emerging drug treatment options for Alzheimer's disease: a systemic review. Drugs, 2011, 71(15): 2031-2065.

Villanueva G, Lopez de Argumedo M, Elizondo I. Dementia drug consumption in the Basque Country between 2006 and 2011. Neurologia, 2014, Nov. 11. pii: S0213-4853(14)00202-3. doi: 10.1016/j. nrl.2014.09.006..
DOI: 10.1016/j. nrl.2014.09.006

Shimizu E, Tang YP, Rampon C, Tsien JZ, NMDA receptor-dependent synaptic reinforcement is a crucial process for memory consolidation. Science, 2000, 290: 1170-74.

Marvanova M, Lakso M, Pirhonen J et al. E. The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Mol. Cel. Neurosci., 2001, 18 (3): 247-258.

Van Dyck CH, Schmitt FA, Olin JT. A responder analysis of memantine treatment in patients in Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry, 2006, 14: 428-37.

Blesa R. Clinical Experience of Memantine in Alzheimer's Disease. European Neurological Review, 2008, 3(2): 22-27.

Peskind ER, Potkin SG, Pomara N et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry, 2006, 14: 704-15.

Bullock R. The needs of the caregiver in the long-term treatment of Alzheimer disease. Alzheimer Dis Assoc Disord, 2004, 18: 17-23.

Cummings JL, Mega M, Gray K et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology, 1994, 44: 2308-14.

Gauthier S, Wirth Y, Mobius H-J. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised controlled trials. Int J Geriatr Psychiatry, 2005, 20: 459-64.

Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry, 2008, Mar., 69(3): 341-8.

Schneider LS, Tariot PN, Dagerman KS et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med, 2006, 355: 1525-38.

Rive B, Vercelletto M, Damier FD, Cochran J, Francois C. Memantine enhances autonomy in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry, 2004, May, 19(5): 458-64.

Wimo A, Winblad B, Stoffler A et al. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics, 2003, 21: 327-40.

Wenk GL, Quack G, Mobius H-J et al. No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci, 2000, 66: 1079-83.

Tariot PN. Medical management of advanced dementia. J Am Geriatr Soc, 2003, 51: 305-13.

Язык текста: Русский

ISSN: 2079-701X